3 April 2024 (Wednesday)

New York 10:00 | London 15:00 | Paris 16:00 | Singapore 22:00 | Tokyo 23:00 | Sydney 01:00 (4th April )

This webinar will focus on recent advancements in the collection and analysis of human breath samples for non-invasive biomarker discovery through to clinical implementation. Owlstone Medical will share some of the latest data from its next-generation Breath Biopsy® OMNI® services platform that enables confident chemical identification and accurate quantitation of a wide range of ‘on-breath’ volatile organic compounds (VOCs). This “Targeted-plus” platform provides both targeted and untargeted analysis from the same sample to maximize the potential for identification and validation of biologically relevant, clinically valuable biomarkers. A range of internal and calibration standards are used to ensure high-quality data alongside a high-resolution accurate mass (HRAM) library of chemical standards to ensure high confidence chemical identification. A wide range of biologically relevant metabolites can be detected on-breath originating from both the airways as well as other organs in the body in addition to the gut microbiome.

In addition to advancements in breath analysis, advancements in the development of a Breath Biopsy VOC Atlas will also be presented. This is a searchable database of VOCs identified with high confidence proven to exist on-breath with quantitative measurements from previous human studies including cohorts of healthy and diseased subjects. This valuable new resource facilitates in silico cross-validation of results via comparison with previous studies to accelerate biomarker development. It also provides links to peer-reviewed literature for individual VOCs and assists in the further elucidation of the relationship between VOCs, biology, and human disease.


Time structure

Duration: 65 minutes
  • 5-min welcome remarks & introductions
  • 45-min presentation
  • 15-min Q&A & closing remarks


Sponsored by